China Pharma (CPHI) Competitors $1.43 -0.03 (-2.05%) Closing price 03:59 PM EasternExtended Trading$1.40 -0.02 (-1.75%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CPHI vs. EQ, FNCH, IMNN, BCAB, ATNF, CMMB, HOTH, ASBP, CVKD, and PASGShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Equillium (EQ), Finch Therapeutics Group (FNCH), Imunon (IMNN), BioAtla (BCAB), 180 Life Sciences (ATNF), Chemomab Therapeutics (CMMB), Hoth Therapeutics (HOTH), Aspire Biopharma (ASBP), Cadrenal Therapeutics (CVKD), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Its Competitors Equillium Finch Therapeutics Group Imunon BioAtla 180 Life Sciences Chemomab Therapeutics Hoth Therapeutics Aspire Biopharma Cadrenal Therapeutics Passage Bio Equillium (NASDAQ:EQ) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has stronger valuation & earnings, EQ or CPHI? China Pharma has lower revenue, but higher earnings than Equillium. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$41.10M0.99-$8.07M-$0.39-2.92China Pharma$4.30M1.09-$3.08MN/AN/A Do analysts rate EQ or CPHI? Equillium currently has a consensus price target of $3.00, suggesting a potential upside of 163.16%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than China Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of EQ or CPHI? 27.1% of Equillium shares are held by institutional investors. 31.6% of Equillium shares are held by company insiders. Comparatively, 17.3% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is EQ or CPHI more profitable? Equillium has a net margin of -19.62% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-19.62% -74.34% -46.75% China Pharma -85.56%-63.93%-31.42% Which has more volatility and risk, EQ or CPHI? Equillium has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Does the media prefer EQ or CPHI? In the previous week, Equillium had 7 more articles in the media than China Pharma. MarketBeat recorded 8 mentions for Equillium and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.50 beat Equillium's score of 0.26 indicating that China Pharma is being referred to more favorably in the news media. Company Overall Sentiment Equillium Neutral China Pharma Positive SummaryEquillium beats China Pharma on 9 of the 14 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$4.67M$811.04M$5.68B$20.89BDividend YieldN/A4.84%4.59%3.57%P/E RatioN/A1.1930.6827.95Price / Sales1.0926.14463.8054.72Price / CashN/A19.5638.2123.95Price / Book2.046.588.995.23Net Income-$3.08M-$4.98M$3.25B$994.11M7 Day Performance-3.70%3.14%4.76%1.78%1 Month Performance-15.88%2.50%6.72%2.03%1 Year Performance-92.10%17.33%30.51%12.80% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina Pharma0.7818 of 5 stars$1.43-2.1%N/A-92.0%$4.67M$4.30M0.00250Short Interest ↓EQEquillium2.8107 of 5 stars$0.60+5.8%$3.00+403.4%+22.7%$20.12M$41.10M-1.5340Earnings ReportShort Interest ↓Gap UpFNCHFinch Therapeutics GroupN/A$12.29-1.4%N/A+18.8%$19.74MN/A-1.39190Gap DownIMNNImunon1.702 of 5 stars$8.76-4.8%$232.50+2,554.1%-54.0%$19.53M$500K-0.4330Short Interest ↑Gap DownBCABBioAtla2.3226 of 5 stars$0.35+5.6%$5.00+1,328.6%-78.3%$19.37M$11M-0.2960News CoverageAnalyst DowngradeAnalyst RevisionATNF180 Life Sciences0.5133 of 5 stars$3.36+5.7%N/A+312.0%$19.20MN/A-0.227News CoverageAnalyst ForecastShort Interest ↑Gap DownCMMBChemomab Therapeutics3.4717 of 5 stars$0.97-3.0%$8.50+776.3%-14.5%$18.86MN/A-1.2820News CoverageEarnings ReportUpcoming EarningsShort Interest ↓HOTHHoth Therapeutics3.1178 of 5 stars$1.38-1.4%$4.00+189.9%+118.6%$18.49MN/A-1.214Earnings ReportShort Interest ↓ASBPAspire BiopharmaN/A$0.35-3.0%N/AN/A$18.06MN/A0.00N/ANews CoverageEarnings ReportCVKDCadrenal Therapeutics2.9294 of 5 stars$10.90+23.7%$32.00+193.6%N/A$18.03MN/A-1.184Earnings ReportShort Interest ↑Analyst RevisionGap UpHigh Trading VolumePASGPassage Bio3.7959 of 5 stars$5.81+1.2%$150.00+2,481.8%-49.4%$17.91MN/A-0.28130News CoverageEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Equillium Competitors Finch Therapeutics Group Competitors Imunon Competitors BioAtla Competitors 180 Life Sciences Competitors Chemomab Therapeutics Competitors Hoth Therapeutics Competitors Aspire Biopharma Competitors Cadrenal Therapeutics Competitors Passage Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access